AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

532

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

December 31, 2026

Conditions

Advanced Squamous Non Small Cell Lung Cancer

Interventions

DRUG

AK112, Carboplatin, Paxlitaxel

IV infusion,Specified dose on specified days

DRUG

Tislelizumab, Carboplatin, Paxlitaxel

IV infusion,Specified dose on specified days

Trial Locations (1)

Shanghai Chest Hospital, Shanghai